In patients with type 2 diabetes and CV disease, empagliflozin reduces CV and all-cause mortality

Mark H. Ebell

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)410
Number of pages1
JournalAmerican Family Physician
Volume93
Issue number5
StatePublished - Mar 1 2016
Externally publishedYes

ASJC Scopus subject areas

  • Family Practice

Cite this